D. Boral Capital analyst Jason Kolbert initiated coverage of Lineage Cell Therapeutics (LCTX) with a Buy rating and $3 price target Lineage is a clinical-stage biotechnology company that specializes in developing innovative cell therapies aimed at treating degenerative diseases, the analyst tells investors in a research note. The firm says the company has a partnership with Roche, focusing on the development and commercialization of OpRegen.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LCTX: